Dan Kidle joined Arboretum Ventures in 2011 as an Analyst.
In his current role as Principal, Dan focuses on supporting Arboretum's portfolio companies and leading new investments across the firm’s sectors of interest, with particular emphasis on life science tools. Since joining Arboretum, Dan has undertaken significant due diligence responsibilities to support more than a dozen of Arboretum’s new and follow-on investments, including Ebb Therapeutics, NeuMoDx, IntelliCyt, Rethink, Cardiac Dimensions, Strata Oncology, SI-BONE, and Swift Biosciences. Dan’s portfolio company involvement has included serving on the board of directors for life science tools company IntelliCyt, until its $90 million acquisition by Sartorius in 2016. Dan currently serves on the Board of Directors for Swift Biosciences and as a board observer for NeuMoDx and Strata Oncology.
Prior to joining Arboretum, Dan was a Financial Analyst at Eli Lilly & Company, supporting the company’s U.S. sales and marketing operations.